{
  "source": "PA-Notification-Sohonos.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1418-2\nProgram Prior Authorization/Notification\nMedication Sohonos™ (palovarotene)\nP&T Approval Date 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nSohonos (palovarotene) is a retinoid indicated for reduction in the volume of new heterotopic\nossification in adults and children aged 8 years and older for females and 10 years and older for\nmales with fibrodysplasia ossificans progressiva (FOP).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Sohonos will be approved based on all of the following criteria:\na. Diagnosis of fibrodysplasia ossificans progressiva (FOP)\n-AND-\nb. One of the following:\n(1) Both of the following:\n(a) Patient is female\n(b) Patient is aged 8 years and older\n-OR-\n(2) Both of the following:\n(a) Patient is male\n(b) Patient is aged 10 years and older\n-AND-\nc. Sohonos is being used to reduce the volume of new heterotopic ossification (HO)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Sohonos will be approved based on the following criterion:\n© 2024 UnitedHealthcare Services, Inc.\n1\na. Documentation of positive clinical response to Sohonos therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Sohonos [package insert]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; August 2023.\nProgram Prior Authorization/Notification - Sohonos (palovarotene)\nChange Control\n10/2023 New program.\n10/202",
    "s:\n1. Sohonos [package insert]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; August 2023.\nProgram Prior Authorization/Notification - Sohonos (palovarotene)\nChange Control\n10/2023 New program.\n10/2024 Annual review with no changes.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}